114474-28-1Relevant articles and documents
Monitoring the hydrogen bond net configuration and the dimensionality of aniline and phenyloxamate by adding 1: H -pyrazole and isoxazole as substituents for molecular self-recognition
Oliveira, Willian X. C.,Do Pim, Walace D.,Pinheiro, Carlos B.,Journaux, Yves,Julve, Miguel,Pereira, Cynthia L. M.
, p. 2818 - 2831 (2019/05/14)
This work describes the synthesis and characterization of a new class of oxamic acid derivatives containing pyrazole and isoxazole as substituents to investigate their ability to form hydrogen bonds aiming at applying them in crystal engineering and molec
BMP-SIGNAL-INHIBITING COMPOUND
-
Paragraph 0692, (2019/11/19)
The present invention relates to novel and excellent small-molecule-corn pounds that specifically antagonize BMP signal pathways, and these compounds can be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus can be used to treat diseases or pathological symptoms related to BMP signal pathway including inflammation, cardiovascular diseases, hematopoietic diseases, cancer, osteodystrophia, or the like, particularly, fibrodysplasia ossificans progressiva, and the present invention relates to provision of a pharmaceutical and pharmacological agent used for specifically antagonizing the BMP signal pathways and acting on the BMP signal pathways in the prevention and treatment or experimental application since the compounds can be beneficial for regulating cell differentiation and/or cell proliferation.
GLUCOSE UPTAKE INHIBITORS
-
Paragraph 0091-0092, (2017/01/09)
Provided hererin are compounds that modulate glucose uptake activityand are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and known transporters/co-transporters of glucose such as GLUT1 and other GLUT family members/alternative hexose transporters. In certain embodiments, the compounds have the structure of formula I: Formula (I) wherein the variables have the values disclosed herein.